Filtered By:
Cancer: Colorectal Cancer
This page shows you your search results in order of relevance. This is page number 14.
Order by Relevance | Date
Total 198 results found since Jan 2013.
Tiny implantable device designed by UCLA scientists helps kill cancer
Many solid tumors resist treatment in part by turning human biology against itself. Tumors surround themselves with extra white blood cells known as regulatory T cells, which call off the body ’s natural defenses against the disease.Strategies to treat cancer by deactivating these cells risk creating other serious problems. Since regulatory T cells play an important role in safeguarding healthy tissues, diminishing them throughout the body can lead to other immune cells mistakenly attacking these tissues and causing autoimmune conditions that damage the colon, liver, heart and other organs.Now, an interdisciplinary UCLA ...
Source: UCLA Newsroom: Health Sciences - January 4, 2023 Category: Universities & Medical Training Source Type: news
< em > Dolomiaea costus: < /em > an untapped mine of sesquiterpene lactones with wide magnificent biological activities
Nat Prod Res. 2023 Jan 10:1-11. doi: 10.1080/14786419.2022.2164577. Online ahead of print.ABSTRACTDolomiaea costus (Falc.) Kasana & A.K. Pandey Family Asteraceae, formerly known as Saussurea costus (Falc.) Lipsch contains a rich treasury of diverse bioactive compounds such as monoterpenes, sesquiterpenes, triterpenes, sterols, cardenolides, flavonoids, coumarins, lignans, phenylpropanoids and alkaloids. The sesquiterpene lactones, costunolide and dehydrocostuslactone in D. costus, possess unique promising in vitro and in vivo biological activities for the prevention and cure of diverse ailments like Parkinson's disease...
Source: Natural Product Research - January 10, 2023 Category: Biochemistry Authors: Ebraheem Abouelwafa Amal Zaki Omar M Sabry Giovanni Caprioli Essam Abdel-Sattar Source Type: research
New STELARA ® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, March 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn’s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.1,2 These data are a part of Janssen’s 22 oral and poster ...
Source: Johnson and Johnson - March 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
